Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Beijing Biostar Pharmaceuticals Co., Ltd. Class H ( (HK:2563) ) is now available.
Beijing Biostar Pharmaceuticals has received a filing notice from the China Securities Regulatory Commission confirming completion of the regulatory filing for its H share full circulation plan, which will allow previously non‑tradable domestic shares to be converted into H shares tradable in Hong Kong. The filing, valid for 12 months, paves the way for the company to apply to the Hong Kong Stock Exchange for conversion and listing of these shares, a move that is expected to enhance share liquidity, broaden the investor base and potentially strengthen the company’s capital-market profile, though the detailed implementation plan is still being finalized and shareholders are urged to exercise caution while trading.
More about Beijing Biostar Pharmaceuticals Co., Ltd. Class H
Beijing Biostar Pharmaceuticals Co., Ltd. is a pharmaceutical company based in Beijing and incorporated in the People’s Republic of China as a joint stock company with limited liability. Its shares are listed on the Hong Kong Stock Exchange under stock code 2563, positioning it within the Hong Kong capital market as a PRC-based drug developer and manufacturer focused on the healthcare and biomedicine sector.
Average Trading Volume: 63,501
Technical Sentiment Signal: Sell
Current Market Cap: HK$758.5M
For a thorough assessment of 2563 stock, go to TipRanks’ Stock Analysis page.